Compare Citius Pharmaceuticals Inc (CTXR) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Materials Select Sector SPDR Fund trades at $50.74. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | XLB | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $53.62 |
52-Week Low | $0.53 | $42.23 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
XLB trades at $50.58, down 0.61% with bearish technical signals from moving averages. The materials ETF faces mixed sentiment as recent sector gains appear priced in, though infrastructure trends provide underlying support. Key support sits at $50 with resistance at $51. Recent analysis suggests limited near-term upside despite sector tailwinds from manufacturing and energy security themes.
Outlook remains cautious with technical indicators favoring bearish momentum. The materials sector benefits from infrastructure spending but faces geopolitical sensitivity and valuation concerns after recent gains. Investment opportunity exists for long-term exposure to industrial materials, though current entry timing appears suboptimal given technical weakness and priced-in cyclical recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
